Inactive Instrument

Dermira, Inc. Stock

US24983L1044

Biotechnology & Medical Research

News in other languages: Dermira, Inc.

10/01/20	USA: Les valeurs à suivre à Wall Street
10/01/20	USA-Les valeurs à suivre à Wall Street (actualisé)
19/03/19	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
19/03/19	USA-Les valeurs à suivre à Wall Street (actualisé)
18/03/19	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street

More news

Managers and Directors: Dermira, Inc.

Manager	Title	Age	Since
Michael Thompson PSD	President	-	-
Carly Loeb COO	Chief Operating Officer	-	01/01/2018
Gary Thompson CMP	Compliance Officer	-	01/01/2018

Director	Title	Age	Since
Gordon Brooks BRD	Director/Board Member	-	20/02/2020
Philip Johnson BRD	Director/Board Member	62	20/02/2020
Michael Thompson BRD	Director/Board Member	-	-

More insiders

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. The Company's portfolio consists of QBREXZA and Lebrikizumab. QBREXZA is a once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients. QBREXZA is applied directly to the skin and is designed to block underarm sweat production by inhibiting sweat gland activation. Lebrikizumab is an injectable, humanized monoclonal antibody targeting interleukin 13 (IL-13) that the Company is developing for the treatment of moderate-to-severe atopic dermatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

11/02/22	QBREXZA Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Payment to Journey Medical Corporation and $7.5 Million to Dermira Inc	CI
30/04/21	Journey Medical Corp completed the acquisition of Qbrexza from Dermira, Inc.	CI
31/03/21	Journey Medical Corp entered into a definitive agreement to acquire Qbrexza from Dermira, Inc. for $160 million.	CI
07/01/21	Evommune, Inc. Enters into an Exclusive License Agreement with Dermira, Inc	CI
12/06/20	Eli Lilly and Company and Dermira Present New Lebrikizumab Phase 2B Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life	CI
20/02/20	Dermira, Inc. Announces Board Changes	CI
20/02/20	Dermira, Inc.(NasdaqGS:DERM) dropped from S&P Global BMI Index	CI
20/02/20	Dermira, Inc.(NasdaqGS:DERM) dropped from S&P TMI Index	CI
19/02/20	Eli Lilly and Company completed the acquisition of 74.8% stake in Dermira, Inc. from a group of sellers.	CI
30/01/20	Dermira : Eli Lilly profit beat helps ease investor concerns over growth	RE
17/01/20	Dermira : Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO	RE
10/01/20	Eli Lilly and Company entered into an agreement and plan of merger to acquire Dermira, Inc. from a group of sellers for $1.1 billion.	CI
10/12/19	Dermira, Inc. Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis	CI

02/03/20	Dermira : Form 15-12B - Securities Registration Termination	PU
20/02/20	Dermira : SEC Filing - S-8 POS	PU
20/02/20	Dermira : SEC Filing - POS AM	PU
20/02/20	Dermira : Lilly Completes Acquisition of Dermira	PR
12/02/20	Dermira : Amended tender offer statement by Third Party	PU

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/20/20 A	Eugene Bauer	Don	Chief Medical Officer; Director	562,325	1.0281%
2/20/20 A	Mark McDade	Issuer sale	Director	68,377	0.1250%
2/20/20 A	Andrew Guggenhime	Issuer sale	Chief Financial Officer	496,361	0.9075%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DERMIRA, INC.	-.--%	+0.11%	-	-	1.03B
WUXI APPTEC CO., LTD.	-3.25%	+13.72%	+52.49%	+88.86%	62.92B
ARGENX SE	+0.69%	+0.96%	+29.39%	+68.41%	54.32B
BIONTECH SE	-1.07%	-1.79%	-18.07%	-14.36%	22.91B
INSMED INCORPORATED	+33.86%	+30.60%	+19.14%	+502.77%	28.73B
WUXI BIOLOGICS (CAYMAN) INC.	+6.81%	+14.09%	+47.24%	+0.80%	21.65B
GENMAB A/S	-0.79%	+1.79%	+36.31%	-25.84%	17.76B
PHARMAESSENTIA CORPORATION	-3.37%	+25.85%	+213.21%	+369.13%	16.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.33%	+9.55%	+32.57%	+668.12%	15.48B
EXELIXIS, INC.	-7.94%	-6.74%	+38.42%	+157.52%	13.12B
Average	+2.93%	+6.57%	+50.08%	+201.71%	28.15B
Weighted average by Cap.	+3.23%	+7.63%	+44.30%	+163.68%

Dermira, Inc. Stock

Stocks

US24983L1044

Biotechnology & Medical Research

Latest news : Dermira, Inc.

Press Releases: Dermira, Inc.

News in other languages: Dermira, Inc.

Managers and Directors: Dermira, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile